Loading clinical trials...
Loading clinical trials...
Biomarker-Guided Feasibility/Efficacy Trial of Ruxolitinib in Patients With High-Risk of Chronic Graft-Versus-Host Disease Development After Allogeneic Hematopoietic Cell Transplantation
Conditions
Interventions
Best Practice
Biomarker Analysis
+3 more
Locations
1
United States
City of Hope Medical Center
Duarte, California, United States
Start Date
June 1, 2026
Primary Completion Date
June 22, 2028
Completion Date
June 22, 2028
Last Updated
April 20, 2026
NCT02474160
NCT07059884
NCT07220447
NCT06600659
NCT06941324
NCT06569316
Lead Sponsor
City of Hope Medical Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions